Federal Register / Vol. 86, No. 10 / Friday, January 15, 2021 / Notices 4105 

Special Emphasis Panel. Member Conflict 

SEP. 

Date: February 26, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Child Health 

and Human Development, 6710B Rockledge 

Drive, Bethesda, MD 20892 (Video-Assisted 

Meeting). 

Contact Person: Helen Huang, Ph.D. 

Scientific Review Officer Scientific Review 

Branch Eunice, Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH Bethesda, MD 20817 301– 

435–8207 helen.huang@nih.gov 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Maternal and 

Pediatric Precision in Therapeutics Hub 

(P50) 

Date: March 9–10, 2021. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Child Health 

and Human Development, 6710B Rockledge 

Drive, Bethesda, MD 20817 (Video-Assisted 

Meeting) 

Contact Person: Christiane M. Robbins, 

Scientific Review Officer Scientific Review 

Branch, (SRB), DER Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, DHHS 6710B 

Rockledge Drive, Rm 2121A Bethesda, MD 

20817 301–451–4989 crobbins@mail.nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, Maternal and 

Pediatric Precision in Therapeutics Hub 

(P30) 

Date: March 11, 2021. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Child Health 

and Human Development, 6710B Rockledge 

Drive, Bethesda, MD 20817 (Video-Assisted 

Meeting) 

Contact Person: Christiane M. Robbins 

Scientific Review Officer Scientific Review 

Branch (SRB), DER Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, DHHS 6710B 

Rockledge Drive, Rm 2121A Bethesda, MD 

20817 301–451–4989 crobbins@mail.nih.gov 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: January 12, 2021. 

Ronald J. Livingston, Jr., 

Program Analyst,Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00924 Filed 1–14–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Review of Dietary 

Biomarker Development Centers (U2C). 

Date: February 17–18, 2021. 

Time: 9:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Video 

Meeting). 

Contact Person: Lan Tian, Ph.D., Scientific 

Review Officer, National Institute of Diabetes 

and Digestive and Kidney Diseases, National 

Institutes of Health, 6707 Democracy 

Boulevard, Room 7349, Bethesda, MD 20892– 

5452, (301) 496–7050, email: tianl@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: January 12, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00920 Filed 1–14–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the National Advisory 

Council on Alcohol Abuse and 

Alcoholism, February 4, 2021, 11:00 

a.m. to February 4, 2021, 5:00 p.m., 

National Institutes of Health, National 

Institute on Drug Abuse, 6700B 

Rockledge Drive, Bethesda, MD, 20892 

which was published in the Federal 

Register on December 21, 2020, 85 FR 

83101. 

This notice is being amended to 

change the end time of the closed 

session as well as the start time and end 

time of the open session of the meeting. 

The closed session will now be held 

from 11:00 a.m. to 12:00 p.m. and the 

open session will now be held from 

12:00 p.m. to 5:30 p.m. The meeting is 

partially closed to the public. 

Dated: January 12, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00921 Filed 1–14–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information may be obtained 

by communicating with Vidita 

Choudhry, Ph.D., Office of Technology 

Transfer and Development, National 

Heart, Lung, and Blood Institute, 31 

Center Drive Room 4A29, MSC2479, 

Bethesda, MD 20892–2479; telephone: 

301–594–4095; email: vidita.choudhry@

nih.gov. A signed Confidential 

Disclosure Agreement may be required 

to receive any unpublished information. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

High-Throughput COVID–19 Diagnostic 

Test That Detects Both Viral and Host 

Nucleic Acid 

The virus that causes COVID–19 is 

designated severe acute respiratory 

syndrome coronavirus 2 (SARS-CoV–2). 

The rapid worldwide spread and impact 

of COVID–19 has created a need for 

accurate, reliable, and readily accessible 

testing on a massive scale. The subject 

invention describes development of a 

4106 Federal Register / Vol. 86, No. 10 / Friday, January 15, 2021 / Notices 

1 50 U.S.C. 4558(c)(1). 

2 85 FR 18403 (Apr. 1, 2020). 

3 DHS Delegation 09052, Rev. 00.1 (Apr. 1, 2020); 

DHS Delegation Number 09052 Rev. 00 (Jan. 3, 

2017). 

massively paralleled multiplexed 

screening method using next generation 

sequencing (NGS). This method uses 

sample-specific barcoded indexes that 

detect both SARS–COV–2 virus and the 

host’s transcriptional response to 

infection simultaneously. By matching 

existing laboratory protocols for PCRbased sample processing, this assay is 

easily incorporated into existing CLIAcertified facilities. This testing approach 

provides the capability for testing tens 

of thousands of patient samples in a 

large bolus, allowing accurate and fastturnaround SARS-CoV–2 testing 

capacity at population scale, and 

permits massive scale monitoring of atrisk individuals with minimal 

processing delay. 

Potential Commercial Applications: 

Diagnostic test for detecting infectious 

organisms, including SARS-CoV–2. 

Competitive Advantages 

• Reduction in reagents needed to 

perform a test, reducing test cost and 

bottleneck of critical reagents used 

during nucleic acid amplification. 

• Simultaneously detect the pathogen 

and a host’s transcriptional response to 

infection by the pathogen. 

• Gene expression information from 

the donor can be used to predict disease 

severity. 

Development Stage: 

• Early stage. 

• Data from tests of human samples 

available. 

Inventors: Ozwaldo Alonso Lozoya 

(NIEHS), and Brian Papas (NIEHS). 

Intellectual Property: HHS Reference 

No. E–241–2020–0; U.S Provisional 

Patent Application 63/116,031 filed 

November 19, 2020. 

Licensing Contact: Vidita Choudhry, 

Ph.D.; 301–594–4095; vidita.choudhry@

nih.gov. This notice is made in 

accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Dated: January 8, 2021. 

Bruce D. Goldstein, 

Director, National Heart, Lung, and Blood 

Institute, Office of Technology Transfer and 

Development. 

[FR Doc. 2021–00825 Filed 1–14–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Maternal and 

Pediatric HIV/AIDS Research. 

Date: March 12, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Child Health 

and Human Development, 6710B Rockledge 

Drive, Bethesda, MD 20817 (Video-Assisted 

Meeting). 

Contact Person: Luis E. Dettin, Ph.D., M.S., 

M.A., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, 6710B Rockledge 

Drive, Rm. 2131B, Bethesda, MD 20892, (301) 

827–8231, luis_dettin@nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Centers to Advance 

Research in Endometriosis (CARE) (P01 

Clinical Trial Not Allowed). 

Date: March 16–17, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6710B 

Rockledge Drive, Rockledge Drive, Bethesda, 

MD 20817 (Video-Assisted Meeting). 

Contact Person: Derek J. McLean, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH, 6710B Rockledge Drive, 

Rm. 2125B, Bethesda, MD 20892–7002, 

Derek.McLean@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: January 12, 2021. 

Ronald J. Livingston, Jr., 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00918 Filed 1–14–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2020–0016] 

Meeting To Implement Pandemic 

Response Voluntary Agreement Under 

the Defense Production Act 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Announcement of meetings. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) held a 

series of meetings to implement the 

Voluntary Agreement for the 

Manufacture and Distribution of Critical 

Healthcare Resources Necessary to 

Respond to a Pandemic. 

DATES: The first meeting took place on 

Wednesday, January 6, 2021, from 2 to 

4 p.m. Eastern Time (ET). The second 

meeting took place on Thursday, 

January 7, 2021, from 2 to 4 p.m. ET. 

The third meeting took place on Friday, 

January 8, 2021, from 2 to 3:30 p.m. ET. 

FOR FURTHER INFORMATION CONTACT: 

Robert Glenn, Office of Business, 

Industry, Infrastructure Integration, via 

email at OB3I@fema.dhs.gov or via 

phone at (202) 212–1666. 

SUPPLEMENTARY INFORMATION: Notice of 

these meetings is provided as required 

by section 708(h)(8) of the Defense 

Production Act (DPA), 50 U.S.C. 

4558(h)(8), and consistent with 44 CFR 

part 332. 

The DPA authorizes the making of 

‘‘voluntary agreements and plans of 

action’’ with, among others, 

representatives of industry and business 

to help provide for the national 

defense.1 The President’s authority to 

facilitate voluntary agreements was 

delegated to the Secretary of Homeland 

Security with respect to responding to 

the spread of COVID–19 within the 

United States in Executive Order 

13911.2 The Secretary of Homeland 

Security has further delegated this 

authority to the FEMA Administrator.3

On August 17, 2020, after the 

appropriate consultations with the 

Attorney General and the Chairman of 

the Federal Trade Commission, FEMA 

completed and published in the Federal 

Register a ‘‘Voluntary Agreement for the 

Manufacture and Distribution of Critical 

Healthcare Resources Necessary to